A Long-term Safety and Efficacy follow-on Study in Participants With Transfusion Dependent Beta-thalassemia Who Have Previously Received OTL-300 (Formerly Know as GSK2696277)) and Completed the TIGET-BTHAL Study
Latest Information Update: 24 Nov 2022
At a glance
- Drugs OTL 300 (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms TIGET-BTHAL
- Sponsors Orchard Therapeutics
- 16 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2019 Planned number of patients changed from 10 to 9.
- 18 Apr 2019 Planned End Date changed from 1 May 2026 to 1 Jun 2026.